Product news

Share this article:
Gilead Sciences has received FDA approval for the marketing of Viread (tenofovir disoproxil fumarate), for the treatment of chronic hepatitis B in adults. Viread has been available in the US for the treatment of HIV infection in adults since 2001.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.